Abstract | BACKGROUND: METHODS: Unbiased RNA sequencing analysis was performed using homogeneous populations of neural stem cells derived from induced pluripotent stem cells in 3 olanzapine responder (reduction of Positive and Negative Syndrome Scale score ≥25%) and 4 nonresponder (reduction of Positive and Negative Syndrome Scale score <25%) inpatients with TRS. We also used a genotyping study from patients with TRS to assess the candidate genes associated with the olanzapine response. CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9-mediated genome editing, neurologic behavioral tests, RNA silencing, and microRNA sequencing were used to investigate the phenotypic mechanisms of an olanzapine resistance gene in patients with TRS. RESULTS: CONCLUSIONS:
|
Authors | Jing Sun, Xiaoya Zhang, Qijie Cong, Dong Chen, Zhenghui Yi, Hailiang Huang, Cong Wang, Mo Li, Rongsen Zeng, Yunxi Liu, Cong Huai, Luan Chen, Chuanxin Liu, Yan Zhang, Yong Xu, Lingzi Fan, Guoqiang Wang, Chuanfu Song, Muyun Wei, Huihui Du, Jinhang Zhu, Lin He, Shengying Qin |
Journal | Biological psychiatry
(Biol Psychiatry)
Vol. 92
Issue 5
Pg. 419-433
(09 01 2022)
ISSN: 1873-2402 [Electronic] United States |
PMID | 35662508
(Publication Type: Journal Article)
|
Copyright | Copyright © 2022 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Antipsychotic Agents
- Neuregulin-1
- Olanzapine
|
Topics |
- Animals
- Antipsychotic Agents
(pharmacology, therapeutic use)
- Humans
- Mice
- Mice, Knockout
- Mitochondria
- Neuregulin-1
(genetics, therapeutic use)
- Olanzapine
(therapeutic use)
- Schizophrenia
(drug therapy, genetics)
- Schizophrenia, Treatment-Resistant
|